- Home
- EEFT vs BBIO Comparison
EEFT vs BBIO Comparison
Compare EEFT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEFT
- BBIO
- Stock Information
- Founded
- EEFT 1994
- BBIO 2015
- Country
- EEFT United States
- BBIO United States
- Employees
- EEFT N/A
- BBIO N/A
- Industry
- EEFT EDP Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- EEFT Technology
- BBIO Health Care
- Exchange
- EEFT Nasdaq
- BBIO Nasdaq
- Market Cap
- EEFT 4.7B
- BBIO 5.1B
- IPO Year
- EEFT 1997
- BBIO 2019
- Fundamental
- Price
- EEFT $107.60
- BBIO $27.57
- Analyst Decision
- EEFT Buy
- BBIO Strong Buy
- Analyst Count
- EEFT 8
- BBIO 13
- Target Price
- EEFT $128.14
- BBIO $47.92
- AVG Volume (30 Days)
- EEFT 220.1K
- BBIO 2.5M
- Earning Date
- EEFT 02-05-2025
- BBIO 11-12-2024
- Dividend Yield
- EEFT N/A
- BBIO N/A
- EPS Growth
- EEFT 27.95
- BBIO N/A
- EPS
- EEFT 6.88
- BBIO N/A
- Revenue
- EEFT $3,900,200,000.00
- BBIO $217,765,000.00
- Revenue This Year
- EEFT $10.39
- BBIO $2,648.47
- Revenue Next Year
- EEFT $7.76
- BBIO N/A
- P/E Ratio
- EEFT $15.45
- BBIO N/A
- Revenue Growth
- EEFT 8.46
- BBIO 2209.77
- 52 Week Low
- EEFT $91.07
- BBIO $21.62
- 52 Week High
- EEFT $117.66
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- EEFT 65.70
- BBIO 57.33
- Support Level
- EEFT $102.40
- BBIO $27.17
- Resistance Level
- EEFT $107.85
- BBIO $29.99
- Average True Range (ATR)
- EEFT 2.50
- BBIO 1.15
- MACD
- EEFT 0.15
- BBIO -0.00
- Stochastic Oscillator
- EEFT 90.04
- BBIO 47.66
About EEFT Euronet Worldwide Inc.
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. The company operates an independent network of ATMs in Europe, along with a network for prepaid products such as mobile top-ups, and processes point-of-sale transactions. It operates in three segment EFT Processing Segment, epay Segment, and Money Transfer Segment. Its segment revenue comes from by operating income, electronical financial transaction processing, mainly generates revenue from monthly ATM management fees and currency conversion transactions. It generates the majority if its geographic revenue from the United States of America.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.